First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study.

18. November 2021

Müller V, Ruhnke M, Hoffmann O, Grafe A, Tomé O, Fett W, Bruch HR, Sommer-Joos AK, Schneeweiss A, 2021.

The Breast, Volume 60, P70-77, 2021.
DOI:https://doi.org/10.1016/j.breast.2021.08.014